Term
Histamine (general and receptors) |
|
Definition
Released from mast cells and basophils by type I hypersensitivity rxns, drugs, venom, and trauma Present at high levels in lungs, skin, and GI tract H1 (Gq protein): inc. capillary dilation --> dec. BP inc. capillary permeability --> inc. edema inc. bronchiolar smooth muscle contraction inc. in peripheral nociceptive receptors --> pain and pruritus dec. AV nodal conduction H2 (Gs protein): inc. gastric acid secrection --> inc. gastric ulcers inc. SA nodal rate, positive inotropism, automaticity |
|
|
Term
|
Definition
MOA: competitive antagonists of histamine All require hepatic metabolism Uses: allergic rxns, hay fever, rhinitis, urticaria, motion sickness, vertigo, N/V w/ pregnancy, pre-op sedation, OTC sleep aids, Parkinsons (acute extrapyramidal symptoms - only 1st gen X BBB) AE: extensions of M block and sedation (additive w/ other CNS depressants) |
|
|
Term
|
Definition
H1 antagonist MOA: +++ on M block, sedation and antimotion widely used OTC |
|
|
Term
|
Definition
H1 antagonist MOA: +++ M block and sedation / ++ antimotion Used for some alpha block and local anesthetic action |
|
|
Term
|
Definition
H1 antagonist MOA: ++ M block, sedation, antimotion SE: possible CNS stimulation |
|
|
Term
|
Definition
H1 antagonist MOA: ++ M block, sedation / ++++ antimotion Uses: highly effective in motion sickness used in N/V of pregnancy |
|
|
Term
|
Definition
H1 antagonist MOA: ++ M block, antimotion / +++ sedation Uses: commonly used for sedative |
|
|
Term
|
Definition
2nd generation H1 antagonist MOA: +/- m block (NO CNS entry) |
|
|
Term
|
Definition
2nd generation H1 antagonist MOA: +/- M block (NO CNS entry) |
|
|
Term
|
Definition
Cimetidine, Ranitidine, Famotidine MOA: Inhibits the H2 receptor for histamine supressing the secretory response of the proton pump after food stimulation and at night Uses: PUD (less effective than PPI's), GERD SE: GI distress, dizziness, somnolence, slurred speech in elderly Cimetidine: major inhibitor of P450 so increases drug effects of quinidine, phenytoin, TCA's warfarin can also dec. androgens --> gynecomastia & dec. libido |
|
|
Term
Omeprazole (other -prazoles) |
|
Definition
MOA: irreversible, direct inhibitors of the proton pump (K+/H+ antiport) in the gastric parietal cell Uses: PUD, GERD, Zollinger-Ellison syndrome (gastrin secreting tumor), eradication regimen for H. pylori SE: dec. bioavailability of drugs that require acid for absorption (fluoroquinolones, ketoconazole) inhibits P450 only small ability |
|
|
Term
|
Definition
MOA: PGE1 analog --> inc. mucus and bicarb secretion and dec. HCl secretion Uses: NSAID induced GI ulcers (NSAIDS inhibit prostaglandins) |
|
|
Term
|
Definition
MOA: polymerizes on GI luminal surface to form a protective gel-like coating of ulcer beds requires an acid pH Uses: inc healing and dec. ulcer recurrence |
|
|
Term
|
Definition
MOA: binds selectively to ulcer coating it and protecting it from acid and pepsin Uses: combined w/ metronidazole and tetracycline to eradicate H. pylori |
|
|
Term
|
Definition
Antacid MOA: neutralize protons in gut of lumen SE: constipation, can inc. oral absorption of weak bases and dec. absorption of weak acids (all antacids) Toxicity: hypophosphatemia, osteodystrophy, dementia |
|
|
Term
|
Definition
Antacid MOA: neutralize protons in gut lumen SE: alkalosis, acid rebound, constipation Toxicity: hypercalcemia |
|
|
Term
|
Definition
Antacid MOA: neutralize protons in gut lumen SE: acid rebound, diarrhea Toxicity: hypermagnesemia (loss of DTR's, respiratory paralysis) |
|
|
Term
|
Definition
Antacid MOA: neutralize proton in gut lumen SE: alkalosis, acid rebound, "gas" |
|
|
Term
|
Definition
Magnesium sulfate: H2O retaining --> inc. intraluminal pressure Bisacodyl: direct intestinal wall stimulant Methylcellulose: collects H2O & swells --> inc. bulk Docusate: detergent --> stool softner Mineral oil: lubricant Lactulose: hyperosmotic |
|
|
Term
|
Definition
Loperamide & Diphenoxylate Opioids that are poorly absorbed |
|
|
Term
Nausea and vomiting (receptors & drugs) |
|
Definition
5HT anatonists: ondansetron DA antagonists: prochlorperazine, metoclopramide H1 antagonists: diphenhydramine, meclizine, promethazine Muscarinic antagonists: scopolamine Cannabinoids: dronabinol NK-1 receptor antagonist: aprepitant (NK-1 used for substance P) |
|
|
Term
5HT 1 receptors (drugs that act on) |
|
Definition
Usu. found in CNS and smooth muscle Buspirone: partial agonist at 5HT 1a receptors (anxiolytic) Sumatriptan: agonist at 5HT 1d receptors in cerebral vessels --> dec. migraine pain SE: of -triptans are asthenia, chest/throat pressure/pain |
|
|
Term
5HT2 recptors (drugs that act on) |
|
Definition
Usu found in CNS (excitatory) in periphery activation --> vasodilation, contraction of GI, bronchial, uterine smooth muscle, and platelet aggregation Olanzapine: atypical antipsychotics at 5HT2a receptors Cyprohepatdine: 5HT2 antagonist used in carcinoid, other GI tumors, postgastrectomy, has marked H1 blocking action used for seasonal allergies |
|
|
Term
5HT3 receptors (drugs that act on) |
|
Definition
Usu found in area postrema, peripheral sensory and enteric nerves MOA: opens ion channels directly w/ no 2nd messengers Odansetron: + other -setrons, antagonists to dec. emesis in chemo, radiation, and post-op |
|
|
Term
5HT4 receptor (drugs that work on) |
|
Definition
found in GI smooth muscle and myenteric nerves Tegaserod: agonist ued in irritable bowel syndrome when assoc. w/ constipation |
|
|
Term
|
Definition
Ergot alkaloid, used in migraine HA's acute attacks MOA: partial agonists at both alpha 1 and 5HT2 recptors in the vasculature (vasoconstrictive action to decrease pulsation in cerebral vessels) SE: GI distress, prolonged vasoconstriction --> ischemia/gangrene Prophylaxis for migraines: propranolol, verapamil, amitriptyline, valproic acid |
|
|
Term
|
Definition
Synthesized from arachidonic acid and released from lipids in cell membranes Membrane phospholipids-->Phospholipase A2--> AA AA (releases both) / \ Cyclooxygenases & Lipoxygenase (COX 1 & COX 2) | Endoperoxides Hydroperoxides (prostaglandins & thromboxane) Leukotrienes Glucocorticoids inhibit phospholipase A2 and COX2 NSAIDS: inhibit cyclooxygenases COXibs: inhibit COX2 Zileuton: inhibits lipoxygenase -leukasts: block leukotrienes (pathway for asthma) |
|
|
Term
Leukotrienes (what drugs inhibit) |
|
Definition
LT (A4, C4, D4) all cause anaphylaxis and bronchoconstriction Glucocorticoids: dec. phospholipase A2 activity which contributes to both antiinflammatory and immunosuppressive actions Zileuton: inhibits liopoxygenase to dec. LTs for asthma tx Zafirlukast: LT receptor antagonist used for tx of asthma |
|
|
Term
Prostaglandins (receptors & drugs) |
|
Definition
PGE1: Misoprostol: analong for tx of NSAID-induced ulcers Alprostadil: maintains patency of ductus arteriosus, vasodilation used in male impotence PGE2: uterine smooth muscle contraction Dinoprostone: used for cervical ripening/ abortifactant PGF2alpha: uterine/bronchiolar contraction Carboprost: abortifacient Latanoprost: tx of glaucoma PGI2: prostacyclin, platelet stabilizer/vasodilator Epoprostenol: used in pulm hypertension PGE2 & PGF2alpha: both increase in primary dysmenorrhea why NSAIDS may work when they inhibit their synthesis |
|
|
Term
|
Definition
TXA2: platelet aggregator (why ASA inhibition is protective post MI), also causes marked bronchoconstriction and vasoconstriction |
|
|
Term
|
Definition
Nonselective inhibitors of cyclooxygenases acting on both COX1 and COX2 to dec. formation of PGs and thromboxanes Analgesic, antipyretic, and antiinflammatory + antiplatelet effects |
|
|
Term
|
Definition
MOA: Irreversible inhibition of COX (covalent bond via acetylation of a serine hydroxyl group near active site) Actions: dose-dependent Antiplatelet: low dose Analgesia and antipyresis: moderate dose antiinflammatory: high doses Uric acid elimination: dec. tubular secretion so hyperuricemia (low dose) & dec. tubular reabsorption so uricosuria (high dose) Acid/base balance: high therapeutic = respiratory alkalosis toxic = inhibit respiration --> respiratory acidosis + uncoupling of oxidative phosphorylation leads to metabolic acidosis SE: Gastic ulcers, salicylism (tinnitus, vertigo, dec. hearing), bronchoconstriction, reye syndrome in kids, inc. bleeding time, renal dysfunction w/ chronic use Tx overdose: gastic lavage, w/ ventilation, inc urine volume and alkalinization of urine |
|
|
Term
|
Definition
Ibuprofen, Naproxen, Indomethacin, Ketorolac, Sulindac Ketorolac has best analgesia All seem to have minimal effects on acid-base Indomethacin: thrombocytopenia, agranulocytosis Sulindac: SJS, hematotoxicity |
|
|
Term
Selective COX2 inhibitors |
|
Definition
Celecoxib, Rofecoxib, valdecoxib MOA: more effective as an antiinflammatory, less GI toxicity, less antiplatelet action Cross-hypersensitivity b/n celecoxib and sulfonamides |
|
|
Term
|
Definition
MOA: inhibition of cyclooxygenases in CNS (NO inhibition of COX in peripheral tissues so lacks ability as antiinflammatory) Uses: antipyretic and analgesic Overdose: hepatotoxicity metabolized by glucuronyl transferase into toxic metabolite N-acetylbenzoquinoneimine which is inactivated by glutathione (in overdose stores are depleted) Antidote: N-acetylcysteine w/in first 12h |
|
|
Term
|
Definition
Disease modifying antirheumatic drugs Hydroxychlorquine: stabilizes lysosomes and dec. chemotaxis (SE: cinchonism) Methotrexate: cytotoxic to lymphocytes (SE: hematotoxicity, mucositis, crystalluria) Sulfasalazine Glucocorticoids Gold salts: dec. lysosomal and macrophage functions (SE: dermatitis, hematotoxicity, nephrotoxicity) Penicillamine: supresses T cells and circulating rheumatoid factor (SE: proteinuria, hematotoxicity) Etanercept: binds TNF (SE: hypersensitivity) Infliximab: monoclonal antibody to TNF (SE: infusion rxns, infxns) Leflunomide Anakinra |
|
|
Term
|
Definition
MOA: binds to tubulin --> dec. microtubular polymerization, dec. LTB4, and dec. leukocyte and granulocyte migration Uses: acute inflammatory gout SE: diarrhea and GI pain w/ longer use = hematuria, alopecia, myelosuppression, gastritis, and peripheral neuropathy |
|
|
Term
|
Definition
MOA: prodrug converted by xanthine oxidase to alloxanthine which inhibits enzyme --> purines and uric acid formation (so dec. blood & urine levels!!) Uses: prophylaxis of chronic gout SE: GI distress, peripheral neuropathy, rash, vasculitits, stone formation, inhibits 6-mercaptopurine metabolism --> bone marrow suppression |
|
|
Term
|
Definition
MOA: inhibits proximal tubular reabsorption of urate, but ineffective if GFR < 50ml/min (so blood levels of uric acid dec and urine levels increase!!!) SE: GI distress, rash, nephrotic syndrome, crystallization of high excretion of uric acid |
|
|
Term
|
Definition
Cortisol (short + mineralocorticoid activity) Prednisone (medium duration) Triamcinolone (intermediate) Betamethasone & Dexamethasone (long-acting) MOA: dec. leukocyte migration, dec. phagocytosis, dec. capillary permeability, inhibits PLA2 (dec. PGs and LTs) Uses: antiinflammatory and immunosuppressive SE: suppression of ACTH, iatrogenic cushingoid syndrome, hyperglycemia (d/t inc. gluconeogenesis) osteoporosis, inc. GI acid and pepsin release, electrolyte imbalance w/ cortisol, dec. skeletal growth in kids, dec. wound healing, inc. glaucoma/cataracts, inc. mental dysfunction |
|
|
Term
Early asthmatic responses |
|
Definition
Assoc. w/ bronchospasm from actions of released histamine and leukotrienes |
|
|
Term
|
Definition
Assoc. w/ infiltration of eosinophils and lymphocytes into airways causing bronchoconstriction and inflammation and mucus plugging |
|
|
Term
3 stimuli for bronchoconstriction (+ which drugs inhibit) |
|
Definition
1. Ach (Ipratropium is the inhibitor) 2. Adenosine (Theophylline is the inhibitor) 3. Leukotrienes ("lukasts" and zileuton are the inhibitors) |
|
|
Term
Stimuli for bronchodilation (+ drugs that encourage) |
|
Definition
1. B2 activators (beta agonists) 2. Phosphodiesterase inhibitors (Theophylline) "inhibit the breakdown of cAMP to AMP so around longer" |
|
|
Term
|
Definition
albuterol, metaproterenol, terbutaline Uses: relief of acute bronchoconstriction and in prophylaxis of exercise-induced asthma salmeterol Uses: longer-acting so not for acute attacks, but use as prevention of nighttime attacks SE: aerosol forms have low potential for systemic toxicity but can cause anxiety, muscle tremors, and CV toxicity w/ overuse |
|
|
Term
|
Definition
MOA: Muscarinic blocker Uses: bronchodilation in acute asthma (esp. COPD) and may be safer than B-blockers in pts w/ CV dz. DOC: for bronchospasm caused by B-blockers |
|
|
Term
|
Definition
MOA: (2) inhibits phosphodiesterase --> increases amt of time cAMP is around and is an antagonist to adenosine Uses: mainly adjunctive, caffeine derivative Toxicities: narrow therapeutic window --> nausea, diarrhea, CV (inc. HR, arrhythmias), and CNS excitation DI: leads to increased toxicity (esp. w/ P40 inhibitors like erythromycin, cimetidine, and fluoroquinolones) |
|
|
Term
|
Definition
MOA: prevent degranulation of pulmonary mast cells, and dec. release of histamine, PAF, and LTC4 from inflammatory cells Uses: prophylactic esp. for sxs of bronchial hyperactivity d/t allergens |
|
|
Term
Beclomethasone, flunisolide, triamcinolone |
|
Definition
MOA: surface-active glucocorticoids that block mediator release and dec. bronchial hypersensitivity by dec. PGs, LTs, and ILs Uses: both acute attacks and prophylaxis SE: may cause oropharyngeal candidiasis and dec in long bone growth in kids Prednisone (oral & IV): generally reserved for severe acute attacks |
|
|
Term
|
Definition
MOA: antagonists at LTD4 receptors Uses: slow onset, so used prophylactically for antigen, exercise, or drug-induced asthma SE: diarrhea, HA, increased infxns |
|
|
Term
|
Definition
MOA: selective inhibitor of lipoxygenases, dec. formation of ALL LTs Uses: more rapid onset, and adjunctive to steroids SE: asthenia, HA, and inc. LFTs |
|
|